logo oncology-news

Онкология  >  Новости онкологии

При финансовой поддержке logo MSD Oncology

Melanoma: add-on trametinib shows PFS, ORR benefit in UK PACMEL study

Phase 2 trial meets primary endpoint in paclitaxel-treated patients.